Clinical Trials Logo

Clinical Trial Summary

Efficacy and Safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (EGFRi)/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor (MEKi)-associated acneiform Rash


Clinical Trial Description

This study is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in cancer participants with EGFRi/MEKi-associated acneiform rash. This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with EGFRi/MEKi-associated acneiform rash. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04697069
Study type Interventional
Source AnaptysBio, Inc.
Contact
Status Terminated
Phase Phase 2
Start date May 4, 2021
Completion date December 13, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04864717 - Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI Phase 4
Active, not recruiting NCT05120362 - A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash N/A
Active, not recruiting NCT05919810 - The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne N/A